Advances in clinical detection methods and nanomaterials for autoimmune liver diseases
Jingjing Chen,
Yaqi Zhu,
Qingcui Wang,
Jinya Ding,
Xiaohua Chen
Affiliations
Jingjing Chen
The Division of Gastroenterology, Department of Internal Medicine at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China
Yaqi Zhu
Department of Clinical Laboratory, Maternal and Child Health Hospital of Hubei Province, Wuhan 430000, China
Qingcui Wang
Department of Clinical Laboratory, General Hospital of Central Theater Command, Wuhan 430070, China; School of Laboratory Medicine, Hubei University of Chinese Medicine, Wuhan 430065, China
Jinya Ding
Department of Clinical Laboratory, General Hospital of Central Theater Command, Wuhan 430070, China
Xiaohua Chen
Department of Clinical Laboratory, General Hospital of Central Theater Command, Wuhan 430070, China; Correspondence to : Department of Clinical Laboratory, General Hospital of Central Theater Command, Wuhan, China.
Autoimmune liver disease (AILD) is a kind of chronic liver disease, due to the autoimmune tolerance of the liver break-down, as well as the imbalance of immune cell numbers and functions led to persistent inflammatory damage of the liver. With the rapid development of diagnoses and treatments, the proportion of liver diseases has changed significantly. Autoimmune liver diseases have gradually become one of the focuses of scholars worldwide. The specificity and sensitivity of diagnostic and prognostic evaluation methods of AILD have always been social concerns of the researchers owing to the variety of etiology, incompletely understood pathogenesis and different clinical phenotypes. This article reviews the current research status and summarizes the research advances and nanomaterials of the diagnosis and prognosis evaluation methods of AILDs.
